Cabaletta Bio said the first two patients have been dosed with rese-cel, an investigational autologous CAR T-cell therapy manufactured using Cellares’ automated Cell Shuttle platform. The production met all release criteria, marking an early proof point for scalable, automated manufacturing intended to improve access and reduce capital intensity. Cabaletta engineered rese-cel (formerly referred to as CABA-201) with a fully human CD19 binder and a 4-1BB co-stimulatory domain. The program is designed for autoimmune diseases, with dosing intended to transiently and deeply deplete CD19-positive cells as part of a single infusion approach. Cellares framed the dosing milestone as evidence that GMP manufacturing and supply-chain execution can be supported via automation for autologous therapies—an area where industry has struggled with process inconsistency and manual bottlenecks.